Nuclea Biotechnologies has agreed to allow Enzo Clinical Labs to offer its HER-2/neu serum assay for undisclosed terms. The assay, which uses blood samples, is designed to help doctors monitor metastatic breast cancer in women whose tumors contain the HER-2/neu protein and make treatment decisions based on the outcomes.

Related Summaries